Join our daily newsletter At The Bell to receive exclusive market insights
- The US Patent & Trademark Office (USPTO) grants patent protection for Medlab Clinical’s (MDC) NanoCelle technology in the United States
- NanoCelle is Medlab’s drug delivery nanotechnology that aims to overcome the current obstacles surrounding drug delivery
- It creates nano-sized water-soluble particles that enable optimised and standardised delivery of medicines
- Patents have now been granted in Australia, New Zealand, Canada, the United States and more than 35 European countries
- Medlab is up 12.5 per cent on the market with shares trading at 18 cents
The US Patent & Trademark Office (USPTO) has granted patent protection for Medlab Clinical’s (MDC) NanoCelle technology in the United States.
The patent is titled “Transmucosal and transdermal delivery systems” and follows a Notice of Allowance received from the UPSTO three weeks ago.
NanoCelle is Medlab’s drug delivery nanotechnology that aims to overcome the current obstacles surrounding drug delivery.
It creates nano-sized water-soluble particles that enable optimised and standardised delivery of medicines.
Patents have now been granted in Australia, New Zealand, Canada, the United States and more than 35 European countries.
Patent protection has also been requested in Hong Kong, with another currently under examination in Singapore.
“This is a very exciting time for Medlab. The United States provides unparalleled opportunities in innovation, investment and commercialisation,” CEO Dr Sean Hall said.
“The granting of NanoCelle US Patent gives Medlab the green-light to pursue potential partnering opportunities in the largest and most powerful marketplace in the world.”
Medlab was up 12.5 per cent on the market with shares trading at 18 cents at 2:40 pm AEDT.
